Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients

Inclusion Criteria: Healthy volunteers: * Males and females aged 18-65 years; * Body Mass Index (BMI) between 18.0 and 28.0 kg/m2; * Non- or ex-smokers who smoked \< 5 pack years and stopped smoking \> 1 year; * Normal blood pressure and heart rate; * Normal electrocardiogram (ECG,12 lead); * Normal laboratory tests; Patients with Asthma: * Males and females aged 21-65 years; * BMI between 18.0 and 28.0 kg/m2; * Non- or ex-smokers who smoked \< 5 pack years and stopped smoking \> 1 year; * Normal blood pressure and heart rate; * Normal ECG (12 lead); * FEV1 ≥ 30% and \< 80% of predicted according to European Coal and Steel Community values (ECSC) * Reversibility of FEV1 ≥ 12% and at least 200 ml of the initial value 15 minutes after inhalation of 200 µg Salbutamol; Patients with COPD: * Males and females aged 40 - 70 years * BMI between 18.0 and 30.0 kg/m2; * Normal blood pressure and heart rate; * Normal ECG (12 lead); * Stable COPD within the past 4 weeks; * Post bronchodilator FEV1 between 30% and 50% predicted values (ECSC); * Post bronchodilator FEV1/FVC \< 0.70 (absolute value); * Minimum smoking history of 10 pack-years; Exclusion Criteria: All subjects: * Blood donation or blood loss in the previous 8 weeks; * Positive HIV1 or HIV2 serology; * Positive acute or chronic Hepatitis B or Hepatitis C; * Unsuitable veins for repeated venipuncture; * Female patients: pregnant, positive pregnancy test, lactating mother or lack of efficient contraception. * History of substance abuse or positive urine drug screen; * Abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation; * Uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric clinically significant disorder; * Participation in another clinical trial in the previous 8 weeks; participation in study using radioactive material within 1 calendar year; * Known sensitivity to Formoterol or Beclometasone or any of the excipients; * Concomitant severe diseases or diseases which are contra indications for the use of inhaled Beta-2-agonist or steroids; * Use of any prescription drug for which concomitant beta-agonist or steroid administration are contraindicated; * Recent relevant infectious disease (less than two months); * Flu vaccination or other vaccination within 4 weeks prior to the screening visit; Additional exclusion criteria for healthy volunteers: * Lung function measurements outside normal limits (normal values: FEV1/FVC \> 0.70 and FEV1 and FVC \> 80% for the ECSC predicted values); Additional exclusion criteria for patients with Asthma: * Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months; * Life-threatening/unstable respiratory status within the previous 30 days; * Requirement of supplemental oxygen therapy; * Change in dose or type of any medications for asthma within 4 weeks prior to the screening visit; * Asthma exacerbation within the 4 weeks prior to inclusion. Additional exclusion criteria for patients with COPD: * Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months; * Life-threatening/unstable respiratory status within the previous 30 days; * Requirement of supplemental oxygen therapy; * Change in dose or type of any medications for COPD within 4 weeks prior to the screening visit; * COPD exacerbation within the 4 weeks prior to inclusion; * History of asthma or any chronic respiratory diseases other than COPD.